ADMA Biologics financials
$9.96−1.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $124.4M | $114.5M | $139.2M | $134.2M | $122.0M | $114.8M | $117.5M | $119.8M | $107.2M | $81.9M | $73.9M | $67.3M |
| Gross profit | $86.3M | $80.8M | $88.8M | $75.6M | $67.2M | $61.1M | $63.3M | $59.7M | $57.5M | $39.1M | $31.1M | $24.7M |
| Gross margin | 69.4% | 70.5% | 63.8% | 56.3% | 55.1% | 53.2% | 53.9% | 49.8% | 53.6% | 47.8% | 42.1% | 36.6% |
| Operating income | $52.4M | $50.3M | $62.8M | $51.0M | $42.8M | $34.9M | $38.3M | $39.6M | $39.2M | $21.8M | $14.2M | $8.7M |
| Net income | $37.8M | $45.3M | $49.4M | $36.4M | $34.2M | $26.9M | $111.9M | $35.9M | $32.1M | $17.8M | -$17.6M | $2.6M |
| Net margin | 30.4% | 39.6% | 35.5% | 27.1% | 28.1% | 23.4% | 95.2% | 30.0% | 29.9% | 21.7% | −23.9% | 3.8% |
| Diluted EPS | $0.16 | $0.19 | $0.20 | $0.15 | $0.14 | $0.11 | $0.45 | $0.15 | $0.13 | $0.08 | $-0.08 | $0.01 |
| EBITDA | $54.2M | $52.1M | $64.8M | $53.0M | $44.9M | $36.9M | $40.3M | $41.6M | $41.3M | $23.9M | $14.2M | $10.8M |
| Operating cash flow | $29.5M | $58.2M | $35.6M | $13.3M | $21.1M | -$19.7M | $50.2M | $25.0M | $45.6M | -$2.2M | $17.6M | $12.0M |
| Free cash flow | $27.3M | $55.7M | $34.6M | -$1.1M | $18.7M | -$24.4M | $47.5M | $24.0M | $43.6M | -$4.6M | $16.4M | $11.2M |
| Diluted shares | 230.3M | 240.0M | 241.7M | 244.7M | 248.6M | 244.7M | 250.0M | 244.8M | 242.2M | 236.4M | 217.5M | 233.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $136.0M | $138.2M | $87.6M | $61.4M | $90.3M | $71.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $196.6M | $196.9M | $72.1M | $72.4M | $73.4M | $73.8M |
| Total assets | $684.2M | $665.2M | $624.2M | $568.7M | $558.4M | $510.6M |
| Total liabilities | $276.0M | $274.9M | $146.9M | $137.5M | $160.1M | $137.2M |
| Shareholders' equity | $408.2M | $390.3M | $477.3M | $431.2M | $398.3M | $373.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology